默克任命Julie Gerberding博士为执行副总裁
美国东部时间2014年12月10日，默克（在美国和加拿大以外的地方称为默沙东）宣布任命59岁的Julie Gerberding博士为全球公共政策与人口健康战略沟通执行副总裁，自12月15日起有效。
Gerberding目前担任默克疫苗部总裁，在这个新设立的执行委员会中，将负责默克公司全球公共政策、企业责任和传播功能，以及默克基金会和默克母亲计划。Gerberding将领导新的合作即加快默克的能力有助于提高人口健康，这项措施的影响正在日益受到各国政府和其他全球性卫生机构的重视。
“Julie一直助力默克疫苗部，尤其在世界上资源有限的国家的新兴市场更容易也更负担得起。”默克董事长及首席执行官Kenneth C. Frazier说道：“疫苗部在Julie的领导下和在公共部门和私立部门的出色业绩使她非常适合领导这些领域，并推进我们与世界各地祖师共同努力推进人口健康。”
Julie Gerberding于2010年1月加入默克公司，任默克疫苗部总裁。此后，默克疫苗影响了更多的人，而默克也开始成为疫苗市场销售的全球领导者。在加入默克期间的2002年到2009年，她在美国疾病预防与控制中心任董事，此前担任医疗保健质量促进处处长。加入CDC之前她是加利福利亚大学旧金山分校传染病学的终身教员，并被聘为临床医学副教授。
“在整个卫生系统中人们都意识到，没有一个组织能够解决我们所面临的复杂挑战。无论是否包含当前的埃博拉疫情、提高疫苗接种率或改善社区人群全体健康，公共和私立部门之间的合作伙伴关系是必不可少的，”Gerberding博士说道：“默克具有独特的作用和责任做出贡献，而卧也非常高兴能有机会带领专家团队帮助我们实现在世界各地拯救生命和改善健康状况的任务。”
Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. In this newly created Executive Committee position, Gerberding, who most recently served as president of Merck Vaccines, will be responsible for Merck’s global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Gerberding will also lead new partnership initiatives that accelerate Merck’s ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.
"Julie has been instrumental in making Merck’s vaccines more accessible and affordable, particularly in emerging markets and many of the world’s most resource-limited countries,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Julie’s leadership of our vaccines business and her exceptional track record in both the public and private sectors make her ideally suited to lead these areas and to advance our engagement with organizations around the world that, like Merck, are working to advance population health.”
Gerberding joined Merck as president of Merck Vaccines in January 2010. Since then, Merck’s vaccines are reaching more people than ever, and Merck became the global leader in the vaccine market based on sales. In addition, the Sanofi Pasteur MSD joint venture in Europe, Merck’s European vaccine business for which Gerberding is the Board co-chair, has improved in both population reach and financial performance. She also helped lead the successful launch in India of the Merck Wellcome Trust non-profit joint venture for vaccine development, the MSD Wellcome Trust Hilleman Laboratories.
Prior to joining Merck, Gerberding served as director of the U.S. Centers for Disease Control and Prevention (CDC) from 2002-2009 and before that served as director of the Division of Healthcare Quality Promotion. Before joining the CDC, Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF.
"People across health systems everywhere are realizing that no single organization can solve the complex challenges we face. Whether containing the current Ebola outbreak, increasing vaccination rates or improving the overall health of people in communities, partnerships between public and private sector organizations are essential,” Dr. Gerberding said. “Merck has a unique role and a responsibility to contribute, and I welcome this opportunity to lead teams of experts who will help us achieve our mission of saving lives and improving health around the world.”
